Pfizer Inc (NYSE:PFE) is trading lower Monday after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.
Pfizer and BioNTech (NASDAQ:BNTX) extended their rolling submission to the FDA seeking to amend the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine to include children aged six months to four years old.
